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 2 
Abstract   17 
In the small intestine, P-glycoprotein (P-gp) may limit the permeability of its substrates, which lead 18 
to reduced oral absorption. To circumvent the effect of P-gp, a nanocomposite material termed 19 
montmorillonite-surfactant hybrid particles was developed. The particles consisted of 20 
montmorillonite, the P-gp-inhibiting, nonionic surfactant, polysorbate 20, and the P-gp substrate, 21 
digoxin. The present study aimed to investigate if montmorillonite-surfactant hybrid particles could 22 
modulate the absorption of digoxin in vivo. Montmorillonite-surfactant hybrid particles were prepared 23 
by lyophilising an aqueous suspension of the constituents. Scanning electron microscopy (SEM), 24 
thermogravimetric analysis (TGA), and powder X-ray diffraction (PXRD) revealed an altered surface 25 
morphology, decreased water content, and intercalation of polysorbate 20 between montmorillonite 26 
layers. The particles were administered orally to Sprague Dawley rats, and digoxin was quantified by 27 
liquid chromatography-tandem mass spectrometry. Control digoxin-containing montmorillonite 28 
decreased the exposure of digoxin. In contrast, montmorillonite-surfactant hybrid particles increased 29 
AUC and Cmax by 31 and 91 %, respectively, compared to digoxin in solution. It was hypothesised 30 
that montmorillonite-surfactant hybrid particles increased digoxin exposure by forming mucosa-31 
localised elevated concentrations of polysorbate 20 and digoxin, which enhanced the inhibitory effect 32 
of polysorbate 20 on P-gp.  33 
Keywords: Intestinal absorption, montmorillonite, nanocomposites, digoxin, P-glycoprotein, 34 
polysorbate 20 35 
Abbreviations: FWHM, the full width at half maximum; LBF, lipid-based formulation; MSH, 36 
montmorillonite-surfactant hybrid, P-gp, P-glycoprotein; SPE, solid phase extraction. 37 
List of compounds studied: Polysorbate 20, montmorillonite, digoxin.  38 
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1 Introduction 39 
Pharmacokinetic properties of drug substances have gained increased focus in early drug 40 
development, as an estimated 10-20 % of drug candidates fail in preclinical development or in clinical 41 
trials, because of undesirable pharmacokinetic properties (Cook et al., 2014; Di and Kerns, 2016; 42 
Kola and Landis, 2004). These undesirable pharmacokinetic properties are often caused by 43 
P-glycoprotein (P-gp) (Di and Kerns, 2016), which is a widely expressed efflux transporter (Thiebaut 44 
et al., 1987). In the apical membrane of the intestinal epithelium, P-gp mediates cellular efflux of 45 
numerous drug substances, which leads to decreased absorption and bioavailability of the drug 46 
substance in question (Leslie et al., 2005; Lin and Yamazaki, 2003).  47 
Numerous nonionic surfactants have been shown to inhibit P-gp in cell- and animal models, albeit in 48 
relatively high concentrations (Al-Ali et al., 2019; Cornaire et al., 2004; Lo, 2003; Zhang et al., 2003). 49 
Polysorbate 20 is among the most potent surfactant-based P-gp inhibitors investigated (Al-Ali et al., 50 
2018a; Al-Ali et al., 2018b; Al-Saraf et al., 2016; Gurjar et al., 2018; Lo, 2003). Co-administration 51 
of 0.55 g kg-1 polysorbate 20 significantly increased the oral bioavailability of the P-gp substrate, 52 
digoxin, in rats from 59 to 84 %, and increased Cmax by 79 % (Nielsen et al., 2016). Corresponding 53 
administration of digoxin to mdr1a knockout rats produced an increased bioavailability, and there 54 
was no effect of co-administration of polysorbate 20 (Nielsen et al., 2016). This suggested that 55 
solubilising effects and/or increased passive permeability were not the cause of the increased 56 
absorption in wild type rats. However, a polysorbate 20 dose of 0.55 g kg-1 corresponds to a dose of 57 
approximately 6 g in humans, when a simple proportional weight scaling is applied (Nair and Jacob, 58 
2016), i.e., more than thrice that of the WHO-recommended maximal daily dose of 25 mg kg-1 59 
(Sheskey et al., 2017). Thus, there is a need to potentiate the effects of polysorbate 20 on P-gp to 60 
develop an applicable polysorbate 20-based formulation for intestinal P-gp inhibition. 61 
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In vitro, only 200 µM (246 µg mL-1) polysorbate 20 was required to completely inhibit P-gp-mediated 62 
digoxin efflux in Caco-2 cells (Nielsen et al., 2016). Meanwhile, 10 % v/v (110 mg mL-1) polysorbate 63 
20 in the dosing solution was necessary to produce the highest observed inhibition of intestinal P-gp 64 
activity, in vivo (Nielsen et al., 2016). This 450-fold difference could be related to the fact that the in 65 
vitro transport system is stationary, while the intestinal lumen is a dynamic system with intestinal 66 
dilution, intestinal transit, and a redundancy in the area able to mediate absorption. Therefore, a 67 
formulation approach may be applied, in which polysorbate 20 and digoxin are released in the vicinity 68 
of the epithelial cells to modify the absorption process. We hypothesise that the clay nanomaterial, 69 
montmorillonite, can be applied as a drug substance- and excipient carrier in this context. 70 
Montmorillonite has previously been investigated as a drug carrier (Aguzzi et al., 2007; Ruiz-Hitzky 71 
et al., 2010). Montmorillonite, like other clays, has a distinct layered structure and surface chemistry, 72 
and montmorillonite elicits a strong ability to retain cations (Hensen and Smit, 2002). Countless 73 
complex possibilities exist when montmorillonite is combined with for example polymers, 74 
surfactants, and dyes to form nanocomposites. Many potential applications have been investigated 75 
from wound dressings to food packaging and waste water treatment (Kokabi et al., 2007; Rhim et al., 76 
2013; Wang and Wang, 2007). However, the application of montmorillonite-based nanocomposites 77 
has received limited attention in the pharmaceutical field. The most common approach has been to 78 
intercalate cationic drug substances between montmorillonite layers to obtain either a modulated drug 79 
release or a solubilising effect on the drug substance in question (Aguzzi et al., 2007). Neutral drug 80 
substances have also been shown to adsorb to montmorillonite surfaces via ion-dipole interactions 81 
(Su and Carstensen, 1972), and montmorillonite has been recognised as a possible solid carrier for 82 
lipid-based formulations (LBF) (Dening et al., 2017; Dening et al., 2018; Feeney et al., 2016). 83 
Calabrese and co-workers have successfully incorporated polysorbate 20 in montmorillonite to obtain 84 
delayed release of cinnamic acid (Calabrese et al., 2016; Calabrese et al., 2017), and they showed that 85 
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polysorbate 20 facilitated the release of cinnamic acid from montmorillonite. Their studies also 86 
confirm the strong interactions between montmorillonite and polymers or surfactants that contain 87 
oxyethylene groups (-CH2-CH2-O-), like polysorbate 20 (Aranda and Ruiz-Hitzky, 1992). 88 
Additionally, it has been shown that montmorillonite has mucoadhesive properties. For example, it 89 
was shown that montmorillonite intercalated with tetracycline displayed mucoadhesive forces to 90 
porcine mucus corresponding to 43 % of chitosan, which is a known highly mucoadhesive 91 
polysaccharide (Iannuccelli et al., 2015). As a result, studies have focused on montmorillonite and 92 
composites hereof to obtain mucoadhesive drug delivery systems for gastroretention or local oral 93 
administration (Aguzzi et al., 2007; Calabrese et al., 2013; Iannuccelli et al., 2015; Onnainty et al., 94 
2016).  95 
Montmorillonite or other clay-based nanomaterials have not been investigated in pharmaceutical 96 
science to obtain modulation of intestinal drug transporters, to our knowledge. Based on literature 97 
findings that montmorillonite has mucoadhesive properties and displays modified drug substance 98 
release in combination with polysorbate 20, we hypothesise that montmorillonite-surfactant hybrid 99 
(MSH) particles intercalated with polysorbate 20 and digoxin may lead to increased exposure of 100 
digoxin, compared to corresponding doses of polysorbate 20 and digoxin in simple solutions. The 101 
present study aimed to prepare and characterise MSH particles and to assess the pharmacokinetics of 102 
digoxin in rats after administration as MSH particles, compared to administration as simple solutions 103 
containing polysorbate 20.  104 
2 Materials and methods 105 
2.1 Materials 106 
Digoxin, triple deuterated (D3)-digoxin, polysorbate 20, bovine serum albumin (albumin fraction V) 107 
> 97 %, montmorillonite as ‘nanoclay, hydrophilic bentonite’, and all other chemicals in analytical 108 
grade quality or higher were from Merck KGaA (Germany). Ultrapure water was obtained from an 109 
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in-house Milli-Q purification system (Millipore, MA, USA). Blank rat plasma was from 110 
Bioreclamation IVT (NY, USA).  111 
2.2 Preparation of montmorillonite-surfactant hybrid particles 112 
MSH particles were prepared with a fixed 1:1 w/w ratio of montmorillonite and polysorbate 20 along 113 
with an amount of digoxin that allowed a constant digoxin dose and variable doses of montmorillonite 114 
and polysorbate 20 (Table 1). Furthermore, two control formulations were prepared. One contained 115 
montmorillonite and digoxin, designated digoxin-containing montmorillonite, and one contained only 116 
montmorillonite, designated lyophilised montmorillonite.  117 
Suspensions of montmorillonite, polysorbate 20, and digoxin were obtained by suspending 118 
montmorillonite in 11.0 mL ultrapure water (Milli-Q) in a beaker fitted with a magnet and stirred for 119 
4 h. The pH was 9.5 after hydration of the montmorillonite suspension, and the pH was subsequently 120 
adjusted to 7.0 ± 0.1 with HCl. In parallel, polysorbate 20 was added to a screwcap vial together with 121 
1000 µL of a 1.00 mg mL-1 digoxin stock solution in 96 % v/v ethanol. The mixture was ultrasonicated 122 
for 30 min to ensure solubilisation of digoxin using an Elmasonic P30H ultrasonic bath (Elma 123 
Schmidbauer, Germany). 12.0 mL of ultrapure water was then added, and the polysorbate 20-digoxin 124 
mixture was ultrasonicated for 60 min to aid micelle formation. Then, the polysorbate 20-digoxin 125 
solution was added to the montmorillonite suspension dropwise (5 min), and the resulting suspension 126 
was stirred for 24 h with the pH maintained at 7.5 ± 0.5 by manual addition of microvolumes of 1 M 127 
HCl. The suspension was divided into ten separate 10 mL lyophilisation vials and stored at -20 oC 128 
overnight. The frozen suspensions were lyophilised in a Beta 2-8 LSCBasic table top freeze dryer 129 
(Martin Christ, Germany). Main drying lasted for 40 h, applying a system pressure of 0.200 mbar, a 130 
shelf temperature of -25 oC, and a condenser temperature of approximately -85 oC. The final drying 131 
lasted for 4 h, applying a system pressure of 0.011 mbar, a shelf temperature of 25 oC, and a condenser 132 
temperature of approximately -85oC. Following lyophilisation, the chamber was filled with dry N2 133 
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gas, and the vials were quickly equipped with rubber stoppers. The total MSH particle content in each 134 
vial was assessed by weighing the vial before filling and after lyophilisation. The products appeared 135 
either as cakes or powders depending on the concentration of montmorillonite in the final suspensions 136 
with increasing montmorillonite amounts resulting in a stable cake.  137 
2.3 Characterisation of MSH particles 138 
The MSH particles were characterised by scanning electron microscopy (SEM), thermogravimetric 139 
analysis (TGA), and powder X-ray diffraction (PXRD).  140 
2.3.1 Scanning electron microscopy 141 
SEM was carried out with a Phenom ProX scanning electron microscope (Thermo Fisher Scientific, 142 
MA, USA). A small amount of powder was mounted on 12 mm stubs with carbon tabs (Agar 143 
Scientific, UK) and coated with gold by a Q150S rotary-pumped sputter coater-carbon coater 144 
(Quorum, UK). Imaging was carried out at an accelerating voltage of 5 kV at magnifications 145 
175-2900 and 10 kV at magnifications 4300-29000.  146 
2.3.2 Thermogravimetric analysis 147 
TGA was carried out on a Q500 thermogravimetric analyser (TA Instruments, TX, USA). Samples 148 
of 2-4 mg was equilibrated at 30 oC for 2 min before the temperature was increased to 700 oC at a 149 
rate of 10 oC min-1. 150 
2.3.3 Powder X-ray diffraction 151 
PXRD was carried out with a PANalytical X’pert PRO multipurpose diffractometer (Malvern 152 
Panalytical, UK). Scanning was performed with a Cu K,  = 1.5406 Å radiation source in the 2 153 
range from 3 to 50 o with a scan speed of 0.254 o s-1 and a step size of 0.0167 o. The voltage and 154 
current were set to 45 kV and 40 mA, respectively. Samples were prepared on 16 mm zero 155 
background plates.  156 
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Miller indices were applied to describe the lattice planes in a sample that caused the observed 157 
reflections in powder X-ray diffractograms. A lattice plane can be described by three integers (hkl), 158 
and the main interest of the present study was the (001) reflection, which is the reflection 159 
corresponding to the distance between two individual montmorillonite layers. Reflections caused by 160 
lattice planes within the individual montmorillonite layers, which were not related to interlayer 161 
distance, can be described as (hk0) reflections. The interlayer spacing of montmorillonite was 162 
calculated from the diffraction angles at maximum intensity of (001) reflections using Bragg’s law:  163 
 n  = 2d sin () (I) 
where n is the number of wavelengths,  is the wavelength of the X-ray source, d is the interlayer 164 
spacing, and  is the diffraction angle. Reflections were assigned by a comparison with literature 165 
(Viani et al., 2002). The full width at half maximum (FWHM) was estimated by manual readouts.  166 
2.4 In vivo study  167 
The study was carried out in accordance with European and Belgian law controlling the experiments 168 
on animals. 60 male Sprague Dawley rats (10 groups, n=6) were supplied from Charles River (MA, 169 
USA) and acclimatised 11-12 days before conductance of the study. At the beginning of the study, 170 
the animals weighed 245-300 g (approximately 9 weeks of age) and were fasted for about 16 h prior 171 
to the experiment.  172 
Animals were dosed by oral gavage with 5 mL kg-1 solutions or suspensions containing 0.02 mg kg-1 173 
digoxin in 40 % v/v ethanol in water. Dosing overview of the individual groups is shown in Table 2. 174 
The amount of ethanol administered did not affect the rats’ clinical behaviour.  175 
Blood samples were taken 15, 30, 45, 60, 120, 180, 240, and 360 min after administration. Micro 176 
sampling was performed by placing the rats in a restrainer and puncturing the tail vein with a 25G 177 
needle. 64 µL of blood was then collected in a glass capillary (Vitrex Medical, Denmark) and closed 178 
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in one end with a sigillum wax plate (Vitrex Medical, Denmark). Capillaries containing blood 179 
samples were placed in centrifuge tubes and kept on ice until centrifugation (1900 G, 4 oC, 10 min). 180 
After centrifugation, the clear part of the capillary, containing plasma, was cut off, and the plasma 181 
was transferred to two 10 µL end-to-end pipettes (Vitrex Medical, Denmark) and placed in two 182 
individually labelled 1 mL Fluid X tubes (Brooks Life Sciences, MA, USA) with lids and stored in a 183 
96-well format. Samples were kept at -20 oC until analysis. The rats were euthanised after the last 184 
blood sample. 185 
2.4.1 Bioanalysis 186 
Calibration standards of digoxin were prepared in rat plasma to obtain concentrations of 187 
2-100 ng mL-1. Quality control samples of 8, 50, and 100 ng mL-1 solutions were prepared by spiking 188 
rat plasma with appropriate amounts of digoxin stock solution. Calibration standards and quality 189 
control samples were stored in 10 µL end-to-end pipettes placed in Fluid X tubes and kept in a freezer 190 
(-20 oC) until sample preparation and were treated like the plasma samples as described below. 191 
 To wash out sample plasma from the end-to-end pipettes, 100 µL 2 % w/v bovine serum albumin in 192 
phosphate buffer (pH 7.5) was added to the sample tubes, and the samples were shaken horizontally 193 
(10 min, 500 min-1) and subsequently centrifuged (5 min, 20 oC, 2300 × g). A 55 µL aliquot of the 194 
sample was then transferred to a new Fluid X tube, and 55 µL internal standard (25 ng mL-1 D3-195 
digoxin in methanol) was added. The pH of the resulting mixture was adjusted to 9 by addition of 25 196 
µL of a 2 M ammonium acetate solution followed by dilution with 175 µL Milli-Q purified water. 197 
The samples were shaken by vortex mixing after each addition. 198 
Oasis® HLB 96 well solid phase extraction (SPE) plates, 30 µm particle size, 30 mg sorbent per well 199 
(Waters, MA, USA) were conditioned with 1 mL methanol, 1 mL Milli-Q purified water, and 3 × 0.5 200 
mL 0.1 M ammonium acetate (pH 9). Positive pressure ( 3 psi) was applied after each addition, until 201 
 10 
the resin was dry. Subsequently, the entire sample volume (310 µL) was transferred to the conditioned 202 
SPE well plates and positive pressure ( 1.5 psi) was applied to load the samples slowly. The SPE 203 
wells were then washed with 3 × 0.5 mL 0.1 M ammonium acetate (pH 9). A positive pressure 204 
( 3 psi) was applied after each addition, until the resin was dry. The samples were then eluted from 205 
the SPE resin with 2 × 0.5 mL and 1 × 0.2 mL ethanol into a new 96-well plate. The eluent was then 206 
dried under a 40 L min-1 flow of dry N2 at room temperature (Porvair Minivap, Porvair Sciences, UK) 207 
and reconstituted in 300 µL 1:1 methanol:water mixture followed by vortex mixing. After a 208 
centrifugation step (10 min, 6000 × g) the samples were transferred to a round 96-well plate for 209 
chromatographic analysis.  210 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was carried out on a 6500 211 
Sciex triple quad instrument (ABSciex, Canada), which was coupled to a UHPLC-system (Shimadzu, 212 
Japan). The chromatographic separation was carried out using a reversed phase UPLC column 213 
(Acquity BEH C18, 1.7 µm, 502.1 mm, Waters, MA, USA). The mobile phases consisted of 0.01 M 214 
ammonium carbonate (solvent A) and methanol (solvent B), and a gradient elution at 45 oC was 215 
performed (starting at 50 % solvent A, 50 % solvent B to 75 % solvent B in 2.3 min, followed by 216 
isocratic hold at 95 % B for 1.19 min and re-equilibration to 50 % B in 0.99 min). Total run time was 217 
4.5 min and a flow rate of 0.3 mL min-1 was applied.  218 
The LC-MS/MS was operated in positive ion mode using the TurboIonSprayTM-interface 219 
(electrospray ionisation), and was optimised for the quantification of digoxin, applying multiple 220 
reaction monitoring (m/z 798.6 → m/z 651).  221 
 The calibration curve ranged from 2-100 ng mL-1 and linear regression with a weighing factor of 1/x2 222 
was used to produce the best fit for the concentration-detector response relationship. The lower limit 223 
of quantification was 2 ng mL-1. The accuracy of all batches, as measured by independent quality 224 
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control samples, were between 80-120 % of the nominal value over the entire range for the plasma 225 
samples.  226 
2.4.2 Data analysis 227 
The AUC of digoxin in the pharmacokinetic profile in the range 0-6 h was calculated by the 228 
trapezoidal method. First order elimination was assumed, and the elimination rate constant (ke) of 229 
digoxin was estimated by performing linear regression of Ln to the plasma concentrations as a 230 
function of time using data points at 2, 3, 4, and 6 h. The slope of the resulting regression was -ke. R
2 231 
values were generally above 0.90. Plasma profiles were also fitted to zero order elimination with a 232 
simple linear regression for the time points stated above. All formulations, except digoxin-containing 233 
montmorillonite, displayed a higher R2 of the fit with first order elimination. It was assumed that the 234 
formulations did not affect elimination, and that the difference observed for digoxin-containing 235 
montmorillonite was caused by prolongation of absorption into the elimination phase, rather than 236 
altered elimination. For this reason, plasma profiles for the treatment with digoxin-containing 237 
montmorillonite was still analysed as first order elimination.  238 





Each analysis of AUC0-6h and elimination was performed for each individual data set, before statistical 240 
analysis.  241 
2.4.3 Statistical analysis 242 
Statistical analysis was performed in GraphPad Prism 8.1.2. The pharmacokinetic parameters, 243 
AUC0-6h, Cmax, the plasma concentration at the first sampling point (C15 min), and t½ of each group of 244 
animals were compared by one-way ANOVA, followed by a Dunnett’s test in the following order: 245 
Co-administration of the three doses of polysorbate 20 was compared to digoxin administered alone, 246 
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and administration of MSH particles A-E was compared to both digoxin administered alone and to 247 
digoxin-containing montmorillonite in two separate analyses. A student’s t test was applied to 248 
compare the pharmacokinetic parameters after administration of digoxin-containing montmorillonite 249 
and digoxin only. All P-values below 0.05 were considered statistically significant.  250 
3 Results  251 
3.1 Characterisation of MSH particles 252 
The untreated montmorillonite was light-brown or beige, as was the lyophilised- and digoxin-253 
containing montmorillonite formulations without polysorbate 20. In contrast, polysorbate 20-254 
containing MSH particle formulations were more pale and had an off-white colour.  255 
3.1.1 Scanning electron microscopy 256 
The shape and surface morphology of the montmorillonite particles was investigated by SEM. 257 
Untreated montmorillonite (Fig. 1A) contained pores of irregular shape with the observed perimeter 258 
diameters in the range 0.8-2.5 µm. The surface morphology of digoxin-containing (Fig. 1B) and 259 
lyophilised montmorillonite (Fig. S2B) appeared similar on the SEM images. Comparison of the SEM 260 
images of untreated montmorillonite with lyophilised montmorillonite and digoxin-containing 261 
montmorillonite, showed that lyophilisation resulted in a more porous structure with pore diameters 262 
of 0.5-3 µm, which was also observed when polysorbate 20 was intercalated (Fig. 1C and D). 263 
Additionally, when polysorbate 20 was intercalated, the pores and the appearance of the particle 264 
surface for MSH particles changed to smoother and more circle- or ellipse-shaped pores, as compared 265 
to digoxin-containing and lyophilised montmorillonite. 266 
The particle shape changed from spheres to irregular particles with sharp edges upon lyophilisation 267 
(Fig. S1). The observed perimeter diameter of the untreated montmorillonite particles was in the range 268 
of 4-50 µm. The irregular MSH particles and digoxin-containing montmorillonite was in the range of 269 
2-200 µm, while lyophilised montmorillonite was in the range of 2-500 µm (Fig. S2A). 270 
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3.1.2 Thermogravimetric analysis 271 
The composition and stability of the starting compounds and the prepared formulations were assessed 272 
by TGA (Fig. 2). The characteristic temperature intervals and corresponding thermogravimetric mass 273 
loss are given in Table S1. Untreated montmorillonite contained 11 % physically adsorbed water and 274 
4 % interlayer water. Dehydroxylation of the untreated montmorillonite accounted for a 3 % mass 275 
loss, resulting in a mass of 83 % left in the pan after heating to 700 oC (residual mass). Polysorbate 20 276 
contained 2 % water and 96 % mass was lost during degradation, which left a residual mass of 1 %. 277 
Lyophilised and digoxin-containing montmorillonite contained less physically adsorbed water than 278 
untreated montmorillonite with 5 and 7 %, respectively, and 4 % interlayer water. Furthermore, 279 
lyophilised and untreated montmorillonite displayed an 87 % and 86 % residual mass, respectively 280 
(Table S1). These residuals correspond to untreated montmorillonite, when corrected for water 281 
content.  282 
MSH particles displayed an even lower content of both physically adsorbed water at 1 % and 283 
interlayer water at 1 %. Degradation of polysorbate 20 led to a 53 % mass loss, and montmorillonite 284 
dehydroxylation accounted for 1 % mass loss, which resulted in a 45 % residual, corresponding to 285 
montmorillonite content. Additionally, comparison of polysorbate 20 and MSH particles showed that 286 
polysorbate 20 decomposed at a lower temperature, when it was incorporated into MSH particles as 287 
the polysorbate 20 degradation was shifted approximately 35 oC down.  288 
3.1.3 Powder X-ray diffraction 289 
The interlayer spacing of montmorillonite in the MSH particles was investigated by PXRD, as shown 290 
in Fig. 3. The interlayer spacing, which was determined from the (001) reflection was 14.9 Å in 291 
untreated montmorillonite and increased to 18.0 Å in MSH particles. The (001) reflection for 292 
untreated montmorillonite displayed a FWHM of 1.66 , while the (001) reflection of MSH particles 293 
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was narrower with a FWHM of 1.00 . Additionally, the (002), (003), (005), and (006) reflections 294 
were present in the MSH particle diffractogram, but not in the untreated montmorillonite 295 
diffractogram. For both digoxin-containing montmorillonite and lyophilised montmorillonite, none 296 
of the (00l) reflections were observed (Fig. 3).  297 
At larger diffraction angles, all formulations showed reflections at approximately 20, 35, and 40 o. 298 
They can all be assigned to (hk0) reflections or combinations including these, which were all 299 
independent of the orientation of the individual montmorillonite layers. Reflections at 29 o were only 300 
present for untreated montmorillonite, digoxin-containing montmorillonite, and lyophilised 301 
montmorillonite.  302 
3.2  In vivo study 303 
The pharmacokinetics of digoxin was investigated in male Sprague Dawley rats, when polysorbate 20 304 
was co-administered in simple solutions and in MSH particles. The pharmacokinetic profiles are 305 
shown in Fig. 4, while obtained pharmacokinetic parameters are summarised in Table 3. The effects 306 
of the applied formulations were most notable on Cmax and C15 min. Overall, the plasma concentration 307 
of digoxin reached a maximum within the first 45 min (Table 3). Elimination generally followed first 308 
order kinetics and there was no apparent correlation between formulation type and t½ (Table 3).  309 
Formulations that contained polysorbate 20 in simple solutions did not alter AUC0-6h. However, they 310 
tended to decrease tmax and increase Cmax and C15 min of digoxin (Fig. 4A). C15 min was increased in a 311 
statistically significant manner for co-administration of 55 and 274 mg kg-1 polysorbate 20 (Table 3).  312 
When digoxin was administered as digoxin-containing montmorillonite, a great alteration of the 313 
pharmacokinetic profile was observed (Fig 4B). Administration of digoxin-containing 314 
montmorillonite resulted in significantly lowered AUC0-6h, Cmax and C15 min, compared to digoxin only 315 
(Table 3), and Cmax/tmax could not clearly be defined (Fig 4B). 316 
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In contrast, when digoxin was administered as MSH particles, containing montmorillonite and 317 
polysorbate 20, AUC0-6h, Cmax, and C15 min all increased 2-4-fold, compared to digoxin-containing 318 
montmorillonite (Table 3). For doses of 137-548 mg kg-1 montmorillonite and polysorbate 20, these 319 
increases were statistically significant. In concordance, the incorporation of polysorbate 20 also led 320 
to decreased tmax (Table 3). Compared to digoxin administered alone, MSH particles increased 321 
AUC0-6h, Cmax and C15 min, and the increase in Cmax and C15 min for the 548 mg kg
-1 MSH formulation 322 
was statistically significant (Table 3).  323 
In some cases, MSH particles also tended to increase both AUC0-6h and Cmax of digoxin, compared to 324 
co-administration of polysorbate 20 in simple solutions in the corresponding doses. For example, co-325 
administration of 548 mg kg-1 polysorbate 20 as MSH particles increased AUC0-6h and Cmax of digoxin 326 
31 % and 32 %, compared to co-administration of 548 mg kg-1 polysorbate 20 in a simple solution 327 
(Fig. 4D).  328 
4 Discussion 329 
4.1 Polysorbate 20 is intercalated in MSH particles  330 
The obtained MSH particles were solid, even though they consisted of 52 % polysorbate 20, which 331 
is liquid at room temperature. This phase transition may occur, because polysorbate 20 was adsorbed 332 
to the montmorillonite surfaces. This was supported by the lighter colour of the MSH particles, which 333 
indicated that polysorbate 20 coated the montmorillonite surface, as also reflected by the particle 334 
morphology according to SEM. Lyophilised montmorillonite, digoxin-containing montmorillonite, 335 
and MSH particles were subjected to the same lyophilisation cycle, but the total water content was 336 
considerably lower in MSH particles. The lower interlayer water content suggested that the 337 
intercalation of polysorbate 20 led to extrusion of water from the interlayer spaces. The destabilisation 338 
of polysorbate 20, when incorporated in MSH particles, as indicated by TGA, was also observed by 339 
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Calabrese and co-workers (Calabrese et al., 2016), and similar trends have been presented with similar 340 
nanocomposites (Liu et al., 2003).  341 
The structure of individual montmorillonite layers was conserved in all the samples, as evident by the 342 
combined (hk0) reflections obtained with PXRD. The (001) reflection shifted to a lower diffraction 343 
angle for MSH particles as compared to untreated montmorillonite, which implied an increased 344 
interlayer distance from 14.9 to 18.0 Å. This 3.1 Å increase agrees well with previous studies 345 
(Calabrese et al., 2016; Calabrese et al., 2017). Under the assumption that the thickness of an 346 
individual montmorillonite layer is 10 Å (Ploehn and Liu, 2006), the resulting distance between 347 
individual montmorillonite layers was 8 Å, corresponding to 5-6 C-C alkane bonds (Skinner, 1945). 348 
This distance indicated a relatively flat conformation of polysorbate 20, and effectively excluded the 349 
possibility of micelle-like bilayer conformations or similar.  350 
The (001) reflection was absent in digoxin-containing and lyophilised montmorillonite, which 351 
implied exfoliation of montmorillonite layers as illustrated in Fig. 5. Furthermore, the appearance of 352 
(002), (003), (005), and (006) and a narrower (001) reflection in the MSH particle diffractogram 353 
suggested increased stacking order. Hence, lyophilisation of montmorillonite suspensions seems to 354 
lead to exfoliation of individual layers. In contrast, when polysorbate 20 was introduced in the 355 
preparation of MSH particles, which were subjected to the same lyophilisation cycle, montmorillonite 356 
layers were not exfoliated. Instead, polysorbate 20 assisted in the stacking of montmorillonite layers 357 
and increased the stacking order of montmorillonite layers. 358 
The presence of the reflection at 29 o for untreated montmorillonite and digoxin-treated 359 
montmorillonite and the absence of the same reflection for MSH particles has not conclusively been 360 
understood. The reflection could simply have been overshadowed in the diffractogram of MSH 361 
particles.  362 
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Characterisation of MSH particles by SEM, PXRD, and TGA have proven a strong interaction 363 
between polysorbate 20 and montmorillonite. Many different interactions between clays and organic 364 
compounds have previously been described (Ruiz-Hitzky et al., 2010). Some of those are also 365 
suggested here: i) ion-dipole interactions between oxyethylene (-CH2-CH2-O-) units of 366 
polysorbate 20 and the negative surface charge of montmorillonite; ii) hydrogen bonding between 367 
end hydroxyl groups of polysorbate 20 and the siloxane surface of montmorillonite.  368 
4.2 Polysorbate 20-containing solutions modulated digoxin pharmacokinetics  369 
The experimental design did not allow for thorough estimation of digoxin absorption rate constant 370 
from the intestine, and for this reason, the first sampling point at 15 min was taken as a rough estimate 371 
of absorption rate. Polysorbate 20 in the simple solution tended to increase Cmax and C15 min and 372 
decreased tmax, which was also shown by Nielsen and co-workers in a previous study (Nielsen et al., 373 
2016). However, in contrast to this previous study, no change was observed in AUC0-6h in the present 374 
study. Overall, AUC-values were generally lower in the present study compared to the study by 375 
Nielsen and co-workers. This may partly be caused by the inclusion of the AUC6-∞ part by Nielsen 376 
and co-workers, which was not included in the present study. The less pronounced effect of 377 
polysorbate 20 on digoxin pharmacokinetics may also partly be attributed to differences in 378 
quantification methods and variation between animals and raw materials. Variation of the 379 
composition between brands and lots of polysorbate 20 is well-documented (Hewitt et al., 2011), 380 
which may influence the function of polysorbate 20 as a P-gp inhibitor. Furthermore, previous studies 381 
on inhibition of intestinal transporters and carriers have also shown a clear modulation of the 382 
pharmacokinetic profile and effects on Cmax and tmax, but with no effects on AUC (Broberg et al., 383 
2012; Nohr et al., 2014). When preceding evidence is considered, the present study still indicates that 384 
polysorbate 20 modulated the pharmacokinetics of digoxin, despite limited statistical strength. The 385 
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modulation of digoxin pharmacokinetics was ascribed to the inhibition of intestinal P-gp, leading to 386 
lowered efflux, and increased intestinal absorption of digoxin.  387 
4.3 Montmorillonite-surfactant hybrid particles increased digoxin exposure 388 
When digoxin-containing montmorillonite was administered, the AUC0-6h, Cmax, and C15 min decreased 389 
compared to digoxin only, likely because of retention of digoxin by montmorillonite in the 390 
formulation, which led to less digoxin available for absorption. This phenomenon has also been 391 
observed by Dening and co-workers (Dening et al., 2018) when the lipophilic and cationic drug 392 
substance, blonanserin, was intercalated into montmorillonite. Dening and co-workers investigated 393 
blonanserin release from montmorillonite in a USP dissolution setup, where only 13 % was released 394 
after 12 h. Accordingly, bioavailability in Sprague Dawley rats for montmorillonite-intercalated 395 
blonanserin was reduced by 35 %, compared to the pure drug suspension (Dening et al., 2018). The 396 
retention of digoxin in the present study showed that montmorillonite can also effectively adsorb 397 
uncharged drug substances. Therefore, montmorillonite alone appeared to be unsuitable for 398 
increasing oral digoxin absorption. Nevertheless, the lowering of digoxin exposure by 399 
digoxin-containing montmorillonite was contrasted by the tendency of the MSH particles to increase 400 
the exposure of digoxin. We therefore suggest that polysorbate 20 facilitated digoxin release from the 401 
MSH particles and also inhibited P-gp activity, leading to an increased digoxin exposure. At present, 402 
it was not possible to unequivocally distinguish these two effects from each other. Additionally, we 403 
suggest that local co-release of digoxin and polysorbate 20 may have caused the observed increased 404 
exposure by elevation of both polysorbate 20- and digoxin mucosal concentrations, compared to 405 
polysorbate 20 and digoxin in simple solutions. However, neither the physicochemical 406 
characterisation nor the in vivo performance of MSH particles have been able to confirm the 407 
underlying mechanism, and further studies of the MSH particle-mucosa interaction are needed.  408 
 19 
When the effects of MSH particles and digoxin-containing montmorillonite are compared, 409 
montmorillonite exhibited a dual function with respect to digoxin retention and enhancement of P-gp 410 
inhibition. This was observed as a decreased digoxin exposure for digoxin-containing 411 
montmorillonite, relative to control, but also as an enhancement of digoxin exposure, when 412 
montmorillonite was intercalated with polysorbate 20 in MSH particles. The observed effects of 413 
digoxin-containing montmorillonite and MSH particles in vivo and the proposed mechanisms have 414 
been illustrated in Fig. 5. 415 
Clays and other solid carriers have also been applied to solidify LBFs, and some examples exists, 416 
where the solidified LBF outperforms the liquid LBF in vivo (Dening et al., 2018; Tan et al., 2013) – 417 
similarly to what have been observed in the present study. For example, a solidified silica-lipid hybrid 418 
formulation of blonanserin tended to increase blonanserin AUC by 24 %, compared to a 419 
corresponding medium-chain triglyceride solution (Dening et al., 2018).  420 
In the present study, polysorbate 20 presented a dual function in MSH particles with the ability to 421 
inhibit P-gp and to facilitate release of digoxin from montmorillonite surfaces. The facilitation of 422 
drug release from montmorillonite by polysorbate 20 was also observed by Calabrese and co-workers 423 
(Calabrese et al., 2017). 100 % release of the anionic compound, cinnamic acid, was achieved after 424 
6 h from a montmorillonite-polysorbate 20 hybrid, whereas only 80 % was released from pure 425 
montmorillonite (Calabrese et al., 2017).  426 
Digoxin-containing montmorillonite retained digoxin and decreased digoxin exposure, while MSH 427 
particles increased digoxin exposure. Therefore, changing the ratio between montmorillonite and 428 
polysorbate 20 in future formulations may produce enhanced polysorbate 20-mediated P-gp 429 
inhibition leading to increased P-gp substrate exposure.  430 
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5 Conclusions 431 
The present study is the first to apply a surfactant-containing nanocomposite material to modulate an 432 
intestinal efflux transporter, to our knowledge. Characterisation of MSH particles showed that 433 
polysorbate 20 affected morphologic appearance of montmorillonite, was intercalated in the 434 
interlayer spaces of montmorillonite, and that polysorbate 20 assisted in ordered stacking of 435 
montmorillonite layers.  436 
In vivo, MSH particles showed a tendency to increase digoxin exposure via P-gp inhibition, both 437 
compared to digoxin administered alone and compared with co-administration of corresponding 438 
polysorbate 20 doses in simple solutions. Furthermore, digoxin-containing montmorillonite, without 439 
polysorbate 20, decreased digoxin exposure. This enhancement in digoxin exposure, when 440 
administered as MSH particles, may be caused by mucosa-localised elevated concentrations of both 441 
digoxin and polysorbate 20, which led to a more effective inhibition of P-gp. However, more research 442 
is required to fully understand the underlying mechanism.  443 
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9 Figure Legends 586 
Fig. 1: Representative scanning electron microscopy images of A) Untreated montmorillonite, B) 587 
digoxin-containing montmorillonite, C) montmorillonite-surfactant hybrid (MSH) particles 588 
formulation A, and D) MSH E. 8700 magnification. Scaling bar = 10 µm.   589 
Fig. 2: Representative runs of thermogravimetric analysis of 2-4 mg aliquots of untreated 590 
montmorillonite (MMT), lyophilised montmorillonite (Lyo-MMT), digoxin-containing 591 
montmorillonite (DG-MMT), montmorillonite-surfactant hybrid particles (MSH), and polysorbate 20 592 
(PS20). Equilibrated at 30 oC, heated to 700 oC at a rate of 10 oC min-1. 593 
Fig. 3: X-ray diffractograms and hkl-indexing of untreated montmorillonite (MMT), lyophilised 594 
montmorillonite (Lyo-MMT), digoxin-containing montmorillonite (DG-MMT), and 595 
montmorillonite-surfactant hybrid particles (MSH) formulation A (representative of all MSH 596 
formulations). Stacked diffractograms, dotted lines represent 0 for each one. Insert: Magnification of 597 
3-8 . Cu K radiation source ( = 1.5406 Å) over the range of 3-50 2 with a scan speed of 0.254  598 
s-1 and a step size of 0.0167 . Intensity in arbitrary units (a.u.). 599 
Fig. 4: Time-concentration profiles of digoxin after oral administration of 0.2 mg kg-1 digoxin to 600 
fasted male Sprague Dawley rats (245-300 g) as solutions or suspensions in 40 % v/v ethanol in water. 601 
Comparisons of A) digoxin administered alone in solution, with co-administration of 55, 274, or 548 602 
mg kg-1 polysorbate 20 (PS20), B) as digoxin-containing montmorillonite (DG-MMT, 548 mg kg-1 603 
MMT) or as montmorillonite-surfactant hybrid (MSH) particles containing 55-137 mg kg-1 604 
polysorbate 20 (PS20) and 55-137 mg kg-1 montmorillonite (MMT) in a 1:1 ratio, and C) as 605 
montmorillonite-surfactant hybrid (MSH) particles containing 274-548 mg kg-1 MMT and 274-548 606 
mg kg-1 PS20 in a 1:1 ratio. D) is an additional representation of selected formulations for direct 607 
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comparison. Values are given as mean ± SEM, n=6. All lines are simple connecting lines for 608 
overview. 609 
Fig. 5. Illustration of the observed effects of the treatment of montmorillonite with digoxin (blue) or 610 
digoxin and polysorbate 20 (red) prior to lyophilisation to form digoxin-containing montmorillonite 611 
and montmorillonite-surfactant hybrid (MSH) particles, respectively. Digoxin-containing 612 
montmorillonite is exfoliated (no stacking order), and MSH particles elicit increased stacking order 613 
and an increase of interlayer distance from 14.9 Å in untreated montmorillonite to 18.0 Å. Overview 614 
of the observed effects in vivo after oral administration of digoxin-containing montmorillonite and 615 
montmorillonite-surfactant hybrid (MSH) particles. 616 
Fig. S1: Scanning electron microscopy images of A) Untreated montmorillonite, B) digoxin-617 
containing montmorillonite, C) montmorillonite-surfactant hybrid (MSH) particles formulation A and 618 
D), MSH E. 430 magnification. Scaling bar = 200 µm. 619 
Fig. S2: Scanning electron microscopy images of lyophilised montmorillonite. A) 430 and B) 8700 620 
magnification. Scaling bars = 10 and 200 µm respectively.  621 
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Table 1. Overview of prepared formulations  
The prepared formulations including the added amounts of montmorillonite, polysorbate 20, and 
digoxin as well as the calculated final content of these (% w/w). 
Formulation 
 
Amount added (mg)  Final content (% w/w) 
 
Montmorillonite Polysorbate 20 Digoxin  Montmorillonite Polysorbate 20 Digoxin 
MSH A 
 
2739 2750 1.00  50 50 0.018 
MSH B 
 
2052 2051 1.00  50 50 0.024 
MSH C 
 
1368 1372 1.00  50 50 0.036 
MSH D 
 
679 689 1.00  50 50 0.073 
MSH E 
 








2738 - 1.00  100 - 0.037 
MSH, montmorillonite-surfactant hybrid  
Table 2. In vivo study overview 
Overview of administered dose of polysorbate 20, montmorillonite, and digoxin along with the amount of 
polysorbate 20 in the dosing formulation (% v/v) for each group of male Sprague Dawley rats.  
Group number 
 
1 2 3 4 
 








MSH particle  
suspension 
Polysorbate 20 in dosing 
formulation (% v/v) 
 
- 1 5 10 
 
-  1 2.5 5 7.5 10 
Digoxin dose (mg kg-1) 
 
0.2 0.2 0.2 0.2 
 
0.2  0.2 0.2 0.2 0.2 0.2 
Polysorbate 20 dose (mg kg-1) 
 
- 55 274 548 
 
-  55 137 274 411 548 
Montmorillonite dose (mg kg-1) 
 
- - - - 
 
548  55 137 274 411 548 
MSH, montmorillonite-surfactant hybrid 
Table 3. Estimated pharmacokinetic parameters. 
Formulation 
AUC0-6h ± SEM 
(µg min mL-1) 
Cmax ± SEM 
(ng mL-1) 





t½ ± SEM 
(h) 
Digoxin 6.05 ± 0.86 29.6 ± 4.9 21.8 ± 1.5 
45 
[30;60] 
2.27 ± 0.15 
+ 55 mg kg-1 polysorbate 20 6.07 ± 0.46 43.8 ± 4.1 37.9 ± 4.6* 
22.5 
[15;48.8] 
1.76 ± 0.18 
+ 274 mg kg-1 polysorbate 20 5.75 ± 0.75 41.1 ± 4.0 35.6 ± 3.1* 
22.5 
[15;33.8] 
1.84 ± 0.16 
+ 548 mg kg-1 polysorbate 20 6.19 ± 0.63 42.6 ± 6.9 34.5 ± 4.2 
30 
[15;45] 
2.42 ± 0.16 
Digoxin-containing montmorillonite (548 mg kg-1 
montmorillonite) 
2.78 ± 0.21* 14.1 ± 0.9* 12.6 ± 1.2* 
37.5 
[15;48.8] 
2.78 ± 0.34 
MSH (55 mg kg-1 montmorillonite & polysorbate 20) 5.14 ± 0.34# 33.0 ± 2.4 27.9 ± 3.5 
30 
[15;45] 
2.46 ± 0.25 
MSH (137 mg kg-1 montmorillonite & polysorbate 20) 6.81 ± 0.59# 51.2 ± 8.0# 37.3 ± 4.3# 
37.5 
[30;45] 
2.54 ± 0.36 
MSH (274 mg kg-1 montmorillonite & polysorbate 20) 6.58 ± 0.66# 50.8 ± 7.5# 49.9 ± 7.9*# 
15 
[15;22.5] 
1.99 ± 0.15 
MSH (411 mg kg-1 montmorillonite & polysorbate 20) 7.71 ± 0.88# 46.7 ± 8.5# 38.6 ± 6.1# 
37.5 
[15;48.8] 
2.30 ± 0.19 
MSH (548 mg kg-1 montmorillonite & polysorbate 20) 7.94 ± 0.66# 56.4 ± 9.0*# 41.1 ± 4.5*# 
30 
[30;45] 
1.94 ± 0.08 
C15 min, the plasma concentration at the first sampling point (15 min); MSH, montmorillonite-surfactant hybrid 
particles. tmax is given as median [25
th percentile;75th percentile]. Significantly different from digoxin only 
marked by * and significantly different from digoxin-containing montmorillonite marked by # (p < 0.05). 
Table S1. Thermogravimetric mass loss of applied formulations by temperature intervals. 
Formulation 
Mass lost (%) in temp. interval 















10.6 2.0 1.6 3.3 82.5 
Lyophilised 
montmorillonite 
5.0 1.9 2.3 3.4 87.4 
Digoxin-containing 
montmorillonite  
7.4 1.7 2.2 2.6 86.1 
Polysorbate 20 2.0 0.3 96.3 0.0 1.4 
MSH particles 0.9 0.5 52.7 1.2 44.7 
MSH, montmorillonite-surfactant hybrid. The defined intervals were ascribed to evaporation (evap.) 
of adsorbed water, interlayer water, polysorbate 20 decomposition (decomp.), and montmorillonite 
dehydroxylation. 
 
